Last edition
News about "Alagille Syndrome"
Health Canada Authorises Livmarli Tablet for Cholestatic Pruritus in Alagille Syndrome
Mirum Pharmaceuticals receives Health Canada approval for Livmarli tablet formulation, expanding dosing options for eligible Alagille syndrome patients with cholestatic pruritus.
Alagille Syndrome | 07/02/2026 | By News Bureau | 118
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members